Algenex, a privately owned biotechnology company, is focused on Research and Development of products to improve Human and Animal Health. Algenex was founded in 2005 as a spin-off of the biotechnology department of INIA (Instituto Nacional de Investigación y Tecnología Agraria, Madrid. Spain). Our platform technology is based on producing high quality recombinant proteins for use in vaccines, diagnostics and therapeutic molecules, eliminating the costly process of fermentation through efficient use of insects as small live bioreactors.

Cangen Biotechnologies was founded in 2000 to develop and market key platform technologies for early cancer detection and technologies to enhance the selection of cancer chemo-sensitivity therapeutic regimes. Cangen's business model is to develop and secure the rights to superior, next-generation cancer detection, chemo-sensitivity and complementary technologies and to rapidly commercialize these technologies.

Champions Biotechnology, Inc. (“Champions”) is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. Our Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice within hours after the sample is taken from the patient, followed by propagation of the resulting xenografts (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor. Biomerk Tumorgrafts™, unlike cell line derived xenografts used in traditional preclinical testing, are never passaged in cell tissue culture. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.